German recombineering company Gene Bridges has completed a commercial licence agreement with Novozymes for the use of its Red/ET recombination technology.
Under the terms of the agreement, Gene Bridges has licensed the Red/ET technology to Novozymes for the purpose of genetically engineering recombinant micro-organisms for use in industrial applications. No financial details were disclosed.
"The Red/ET system is a very powerful technology, and we look forward to using it to accelerate our strain development efforts," said Dr Alan Berry, director, microbial physiology and HTS at Novozymes in Davis, California.
Red/ET is a revolutionary method for DNA engineering. Recombineering with Red/ET allows unlimited cloning, subcloning, and modification of DNA at any chosen position. It permits precise engineering of DNA molecules of any size, including very large ones such as BACs or the E.coli chromosome.
